Smith & Nephew signs option on Helix BioMedix peptide:
This article was originally published in Clinica
Executive Summary
Smith & Nephew has signed a memorandum of understanding with biotech peptide specialist, Helix BioMedix, under which the UK orthopaedics group has a right of first offer to license rights to various wound-related indications for one of the Bothell, Washington-based firm's peptides. Under such an arrangement, S&N would contribute its expertise in wound management to the development of the product as a topical anti-infective. The peptide, HB50, could be a useful tool in the fight against MRSA, among other pathogens.